Spinraza

Pharma

Biogen undeterred after FDA snub for high-dose Spinraza in SMA

Despite possessing solid data on high-dose Sprinraza in spinal muscular atrophy, Biogen must revise its application if it hopes to secure an approval.

Fraiser Kansteiner Sep 24, 2025 9:51am

Roche picks up FDA nod for easier Evrysdi dosing format in SMA

Feb 12, 2025 2:30pm

Biogen reports promising results for higher dose of Spinraza

Oct 9, 2024 7:30am

Biogen to seek approval for high-dose version of Spinraza

Sep 4, 2024 11:45am

Biogen CEO plots turnaround after 'weak' 2023 performance

Feb 13, 2024 11:28am

Biogen pays $7.3B to acquire Reata and newly approved Skyclarys

Jul 28, 2023 11:17am